Last10K.com

Trillium Therapeutics Inc. (TRIL) SEC Filing 40-F Annual report for the fiscal year ending Wednesday, December 31, 2014

SEC Filings

TRIL Valuations

Intrinsic Value
Financial Stability
Financial Ratios
Insider Trades
Manager Portfolios
Notifications

TRIL Annual Reports

TRIL Quarterly Reports

TRIL Corporate News

TRIL Corporate News

Trillium Therapeutics Inc.

HISTORY TOOLS
CIK: 1616212 Ticker: TRIL

View differences made from one year to another to evaluate Trillium Therapeutics Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 40-F Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Trillium Therapeutics Inc..

Continue

Assess how Trillium Therapeutics Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Trillium Therapeutics Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2015 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools
Ticker: TRIL
CIK: 1616212
Form Type: 40-F Annual Report
Accession Number: 0001062993-15-001454
Submitted to the SEC: Tue Mar 24 2015 5:08:35 PM EST
Accepted by the SEC: Tue Mar 24 2015
Period: Wednesday, December 31, 2014
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/tril/0001062993-15-001454.htm